MY APPROACH

My approach to and thoughts on the typing of ovarian carcinomas

W G McCluggage

Correspondence to:
Professor W Glenn McCluggage, Department of Pathology, Royal Group of Hospitals Trust, Grosvenor Road, Belfast BT12 6BL, Northern Ireland, UK; glenn.mccluggage{at}belfasttrust.hscni.net

Ovarian carcinomas of epithelial type comprise a heterogeneous group of neoplasms, each with a different underlying pathogenesis and natural behaviour. Accurate classification of ovarian carcinomas is important since each type may be associated with a different behaviour, natural history and outcome. Precise classification is also critical to determine whether alternative therapeutic strategies are appropriate for different tumour types. Previous studies have shown significant interobserver variation in the typing of ovarian carcinomas. There are several areas where there are particular difficulties; these include the distinction between high-grade serous and endometrioid adenocarcinomas and the distinction between a true clear cell carcinoma and clear cell areas within other adenocarcinomas. This review details my approach to the typing of ovarian carcinomas. Morphological assessment, which remains the mainstay in diagnosis, can be supplemented by immunohistochemistry which, for example, is useful in the distinction between serous carcinomas (WT1 positive) and other carcinomas (generally WT1 negative). In recent years, there has been emerging new information regarding the major underlying molecular events in several types of ovarian carcinoma. This has resulted in the acceptance that there are two distinct types of ovarian serous carcinoma. These are termed low-grade and high-grade serous carcinoma, but represent two distinct tumour types rather than low-grade and high-grade variants of the same neoplasm. The integration of clinical, morphological and molecular data has resulted in a more precise classification of ovarian carcinomas and has resulted in the proposal for a broad dualistic pathway of ovarian epithelial carcinogenesis with, in general, low-grade type 1 tumours evolving from benign and borderline neoplasms through a well-defined adenoma–carcinoma sequence, and high-grade type 2 neoplasms arising from an, as yet, undefined precursor lesion.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Cochrane, D. R., Spoelstra, N. S., Howe, E. N., Nordeen, S. K., Richer, J. K. (2009). MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Molecular Cancer Therapeutics 8: 1055-1066 [Abstract] [Full Text]  
• Tan, D. S.P., Lambros, M. B.K., Rayter, S., Natrajan, R., Vatcheva, R., Gao, Q., Marchio, C., Geyer, F. C., Savage, K., Parry, S., Fenwick, K., Tamber, N., Mackay, A., Dexter, T., Jameson, C., McCluggage, W. G., Williams, A., Graham, A., Faratian, D., El-Bahrawy, M., Paige, A. J., Gabra, H., Gore, M. E., Zvelebil, M., Lord, C. J., Kaye, S. B., Ashworth, A., Reis-Filho, J. S. (2009). PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas. Clin. Cancer Res. 15: 2269-2280 [Abstract] [Full Text]  
• Clarke, B, McCluggage, W G (2009). Iatrogenic lesions and artefacts in gynaecological pathology. J. Clin. Pathol. 62: 104-112 [Abstract] [Full Text]  
• Miller, K, Price, J H, Dobbs, S P, McClelland, R H, Kennedy, K, McCluggage, W G (2008). An immunohistochemical and morphological analysis of post-chemotherapy ovarian carcinoma. J. Clin. Pathol. 61: 652-657 [Abstract] [Full Text]